39 research outputs found
Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina
Configuration of the drainage angle, intraocular pressure, and optic disc cupping in subjects with chronic angle-closure glaucoma
10.1016/j.ophtha.2004.06.033Ophthalmology112128-32OPHT
Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma
Ophthalmology1113427-434OPHT
Angle closure glaucoma - Diagnosis and treatment. From the World Glaucoma Congress held in Vienna, Austria, 6-9 July 2005
Asian Journal of Ophthalmology74158-165AJOS
Selective laser trabeculoplasty for primary angle closure with persistently elevated intraocular pressure after iridotomy
PURPOSE: To determine whether selective laser trabeculoplasty (SLT) can lower intraocular pressure (IOP) in eyes with chronic primary angle closure, elevated IOP, and a patent iridotomy. PATIENTS AND METHODS: Patients with chronic angle closure who had underwent iridotomy, had an IOP greater than 21 mm Hg and a gonioscopically visible pigmented trabecular meshwork for at least 90 degrees were enrolled. SLT was applied to open angle segments. Duration of follow-up was 6 months. RESULTS: Sixty eyes of 60 patients were enrolled. The mean baseline IOP was 24.6±2.5 mm Hg. At 6 months, IOP reduction of ≥3 mm Hg or 4 mm Hg was measured in 82% and 72% of eyes, respectively, and IOP reduction of ≥20% or 30% was measured in 54% and 24% of eyes, respectively. When only eyes that were treated with the same number or fewer medications were considered, these IOP reductions were measured in 67%, 58%, 43%, and 15%, respectively. During the study period 1 eye (1.7%) required trabeculectomy owing to IOP elevation shortly after the SLT. There were no other significant complications attributable to SLT. CONCLUSIONS: SLT seems to be a safe and effective method of reducing IOP in many eyes with primary angle closure and a patent iridotomy in which there is a sufficient extent of visible trabecular meshwork. © 2009 Lippincott Williams & Wilkins, Inc.link_to_subscribed_fulltex